newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

COAG
  • Hemab Therapeutics presented five oral presentations across three programs at the ISTH 2026 Congress in Paris, France.
  • New clinical data for HMB-002 demonstrated a 2.4-fold increase in Von Willebrand Factor & Factor VIII levels, confirming proof of mechanism for Von Willebrand Disease.
  • The company unveiled HMB-003, a novel non-hormonal peptide-based plasmin inhibitor designed to reduce bleeding in heavy menstrual bleeding & other settings.
  • Long-term extension data for sutacimig showed sustained bleed reduction in Glanzmann thrombasthenia, with the FDA endorsing the data package to proceed to a Phase 3 pivotal trial.
  • The Phase 3 trial for sutacimig in Glanzmann thrombasthenia is planned to initiate in the second half of 2026.
  • Preclinical data for sutacimig in Factor VII deficiency showed binding across 22 of 25 tested variants, supporting the ongoing Phase 2 trial with data expected in late 2026 or early 2027.
  • First-in-human studies for HMB-003 are planned to begin in the second half of 2026, with initial clinical data expected mid-2027.
  • Cash, cash equivalents, & marketable securities totaled $457.5 million as of June 30, 2026, providing a runway into 2029 following a $317.2 million IPO.
  • Research & development expenses were $20.3 million for the second quarter of 2026, while general & administrative expenses were $5.7 million.
  • The company reported a net loss of $24.2 million, or $0.80 per share, for the three months ended June 30, 2026.